| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
3,5-O-Dicaffeoylquinic acid targets oxidative stress pathways through its potent antioxidant activity. The compound scavenges free radicals and protects cells against oxidative damage. It also has anti-inflammatory activity, modulating inflammatory pathways and reducing pro-inflammatory cytokine production. Its hepatoprotective effects suggest interactions with liver cells and protection against liver damage. The compound may also modulate glucose metabolism, contributing to its antidiabetic effects.
|
|---|---|
| ln Vitro |
3,5-O-Dicaffeoylquinic acid exhibits potent antioxidant activity in vitro by scavenging free radicals and protecting cells against oxidative damage. The compound has anti-inflammatory activity, reducing pro-inflammatory cytokine production. It shows hepatoprotective effects by protecting liver cells from damage. These in vitro findings support its potential applications in oxidative stress research, inflammation research, and liver disease research.
|
| ln Vivo |
In vivo studies of 3,5-O-Dicaffeoylquinic acid have demonstrated its hepatoprotective and anti-inflammatory effects. The compound has been studied in animal models of liver disease, where it protects liver cells from damage. Its antioxidant activity contributes to protection against oxidative stress in vivo. The compound's anti-inflammatory effects have been observed in models of inflammation. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro antioxidant assays for 3,5-O-Dicaffeoylquinic acid typically involve testing its ability to scavenge free radicals using DPPH, ABTS, or FRAP assays. Anti-inflammatory activity is assessed by measuring inhibition of pro-inflammatory cytokine production in immune cells. Hepatoprotective activity is evaluated using liver cell lines treated with hepatotoxic agents. The compound's purity and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for 3,5-O-Dicaffeoylquinic acid involve culturing liver cells to evaluate its hepatoprotective effects. Cells are treated with varying concentrations of the compound and exposed to hepatotoxic agents; cell viability is assessed using MTT or similar colorimetric assays. For anti-inflammatory studies, immune cells are treated and cytokine production is measured. For antioxidant studies, cells are treated and exposed to oxidative stress inducers. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for 3,5-O-Dicaffeoylquinic acid would be conducted to evaluate its hepatoprotective, anti-inflammatory, and antioxidant activities. For liver disease studies, animals with induced liver damage would be treated and liver function assessed. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. Parameters assessed would include liver enzymes, inflammatory markers, oxidative stress markers, and tissue histopathology. Control groups receiving vehicle alone would be included for comparison.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3,5-O-Dicaffeoylquinic acid reflect its nature as a polyphenolic compound. It has a molecular weight of 516.45 and the molecular formula C25H24O12. As a polyphenol, it would be absorbed through the gastrointestinal tract and metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3,5-O-Dicaffeoylquinic acid has been evaluated in the context of its use as a research chemical. As a naturally occurring polyphenol found in coffee and other plants, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
3,5-Di-O-caffeoylquinic acid is a carboxylic acid ester, a diester formed by the condensation of the hydroxyl groups at the 3 and 5 positions of (-)-quinic acid with the carboxyl groups of trans-caffeic acid. It was isolated from Brazilian propolis and Suaeda glauca and possesses hepatoprotective and cytotoxic activities. It functions as a metabolite, hepatoprotective agent, and antitumor agent. It is a cyclic alcoholic carboxylic acid and carboxylic acid ester. Its function is related to (-)-quinic acid and trans-caffeic acid. Isochlorogenic acid A has been reported in Farfugium japonicum, Artemisia princeps, and other organisms with relevant data. See also: 3,5-Di-O-caffeoylquinic acid (note moved to).
3,5-O-Dicaffeoylquinic acid (CAS# 89919-62-0) is a naturally occurring polyphenolic compound belonging to the class of dicaffeoylquinic acids. It has the molecular formula C25H24O12 and a molecular weight of 516.45. The compound exhibits potent antioxidant, anti-inflammatory, and hepatoprotective activities. It has been studied for its potential therapeutic applications in liver diseases, diabetes, and neurodegenerative disorders. |
| Molecular Formula |
C25H24O12
|
|---|---|
| Molecular Weight |
516.45
|
| Exact Mass |
516.126
|
| CAS # |
89919-62-0
|
| PubChem CID |
6474310
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
826.2±65.0 °C at 760 mmHg
|
| Flash Point |
280.4±27.8 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.719
|
| LogP |
1.05
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
825
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C(C[C@H](C([C@@H]1OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)(O)C(=O)O
|
| InChi Key |
KRZBCHWVBQOTNZ-RDJMKVHDSA-N
|
| InChi Code |
InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(30)36-19-11-25(35,24(33)34)12-20(23(19)32)37-22(31)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-29,32,35H,11-12H2,(H,33,34)/b7-3+,8-4+/t19-,20-,23?,25?/m1/s1
|
| Chemical Name |
(3R,5R)-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (193.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (4.84 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9363 mL | 9.6815 mL | 19.3630 mL | |
| 5 mM | 0.3873 mL | 1.9363 mL | 3.8726 mL | |
| 10 mM | 0.1936 mL | 0.9681 mL | 1.9363 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
